Gritstone bio jumps on patents for mRNA vaccine platform technology

Gritstone bio

13/12/2022 17:08

** Shares of drug developer Gritstone bio  GRTS.O  jump ~27%
to $3.27, among top pct gainers across U.S. exchanges
    ** Set for biggest one-day pct gain in nearly 2 years
    ** Co says United States Patent and Trademark Office issued
two new patents related to co's self amplifying mRNA vaccine
platform technology
    ** One patent covers co's lead product, GRANITE, which is a
individualized cancer vaccine candidate
    ** The other patent covers antigen-encoding samRNA vectors
and has broad applicability across co's candidates in oncology
and infectious disease - GRTS
    ** Self amplifying mRNA replicates once in the cell,
creating copies of the original strand of RNA, unlike
traditional mRNA
    ** Despite session's gain, stock down ~75% YTD 
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))